COMP and neoplasm: In contrast, the COMP immunohistochemical stains in this relatively small group of metastatic patients (n = 39) failed to show any difference (p = 0.518) in median OS between patients that had a strong (score 3) expression of COMP in tumor or stroma cells (median OS: 0.7 years, 95% CI: 0.0–2.0) and those who had a weak expression (score 0–2) (median OS: 0.5 years, 95% CI: 0.1–0.9; Figure 1D).